AU2015401587A1 - Methods of treating cancer by administering a MEK inhibitor in combination with a proteasome inhibitor - Google Patents

Methods of treating cancer by administering a MEK inhibitor in combination with a proteasome inhibitor Download PDF

Info

Publication number
AU2015401587A1
AU2015401587A1 AU2015401587A AU2015401587A AU2015401587A1 AU 2015401587 A1 AU2015401587 A1 AU 2015401587A1 AU 2015401587 A AU2015401587 A AU 2015401587A AU 2015401587 A AU2015401587 A AU 2015401587A AU 2015401587 A1 AU2015401587 A1 AU 2015401587A1
Authority
AU
Australia
Prior art keywords
cancer
mek
hsf1
cells
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015401587A
Other languages
English (en)
Inventor
Chengkai DAI
Zijian Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jackson Laboratory
Original Assignee
Jackson Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jackson Laboratory filed Critical Jackson Laboratory
Publication of AU2015401587A1 publication Critical patent/AU2015401587A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015401587A 2015-07-09 2015-08-11 Methods of treating cancer by administering a MEK inhibitor in combination with a proteasome inhibitor Abandoned AU2015401587A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190563P 2015-07-09 2015-07-09
US62/190,563 2015-07-09
PCT/US2015/044662 WO2017007495A1 (en) 2015-07-09 2015-08-11 Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor

Publications (1)

Publication Number Publication Date
AU2015401587A1 true AU2015401587A1 (en) 2018-02-01

Family

ID=57685946

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015401587A Abandoned AU2015401587A1 (en) 2015-07-09 2015-08-11 Methods of treating cancer by administering a MEK inhibitor in combination with a proteasome inhibitor

Country Status (6)

Country Link
US (1) US20180369203A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018520164A (cg-RX-API-DMAC7.html)
KR (1) KR20180021198A (cg-RX-API-DMAC7.html)
AU (1) AU2015401587A1 (cg-RX-API-DMAC7.html)
CA (1) CA2991777A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017007495A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115151533B (zh) 2020-01-10 2025-08-08 医疗免疫工程公司 Mek抑制剂及其治疗用途
WO2023147297A2 (en) * 2022-01-25 2023-08-03 Verastem, Inc. Combination therapy for treating abnormal cell growth
CN115120731A (zh) * 2022-07-12 2022-09-30 四川大学华西医院 一种靶向蛋白酶体治疗乳腺癌的药物应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370568B1 (en) * 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
US20150071918A1 (en) * 2012-05-09 2015-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptides for the treatment of cancer
CN105163584B (zh) * 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物

Also Published As

Publication number Publication date
WO2017007495A1 (en) 2017-01-12
JP2018520164A (ja) 2018-07-26
CA2991777A1 (en) 2017-01-12
KR20180021198A (ko) 2018-02-28
US20180369203A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
Tang et al. MEK guards proteome stability and inhibits tumor-suppressive amyloidogenesis via HSF1
Gallo et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition
Marchi et al. Akt‐mediated phosphorylation of MICU1 regulates mitochondrial Ca2+ levels and tumor growth
Zhang et al. Curcumin induces endoplasmic reticulum stress-associated apoptosis in human papillary thyroid carcinoma BCPAP cells via disruption of intracellular calcium homeostasis
Qu et al. In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma
Cheng et al. YM155 down‐regulates survivin and XIAP, modulates autophagy and induces autophagy‐dependent DNA damage in breast cancer cells
Martínez-Carreres et al. CDK4 regulates lysosomal function and mTORC1 activation to promote cancer cell survival
Liu et al. Cdk5 links with DNA damage response and cancer
Xu et al. IU1 suppresses proliferation of cervical cancer cells through MDM2 degradation
Zhang et al. Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy
Chen et al. CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway
Chao et al. ATM‐and ATR‐induced primary ciliogenesis promotes cisplatin resistance in pancreatic ductal adenocarcinoma
Lone et al. Non-POU domain-containing octomer-binding (NONO) protein expression and stability promotes the tumorigenicity and activation of Akt/MAPK/β-catenin pathways in human breast cancer cells
Huang et al. BCL-W is a regulator of microtubule inhibitor-induced mitotic cell death
Xie et al. Centrosomal localization of RXRα promotes PLK1 activation and mitotic progression and constitutes a tumor vulnerability
Liu et al. RETRACTED: Arginine methylation of SHANK2 by PRMT7 promotes human breast cancer metastasis through activating endosomal FAK signalling
US20180369203A1 (en) Methods of treating cancer by administering a mek inhibitor in combination with a proteasome inhibitor
Huang et al. Stabilizing MARCH7 as a ferro-guardian against ferroptosis
Hasanain et al. Microtubule disrupting agent‐mediated inhibition of cancer cell growth is associated with blockade of autophagic flux and simultaneous induction of apoptosis
Zhang et al. CaMKII suppresses proteotoxicity by phosphorylating BAG3 in response to proteasomal dysfunction
Chikkegowda et al. Design, synthesis, characterization, and crystal structure studies of Nrf2 modulators for inhibiting cancer cell growth in vitro and in vivo
Sun et al. KDM5B-driven glucose metabolic reprogramming promotes enzalutamide resistance in prostate cancer via the lactate/hnRNPA1 lactylation/AR-V7 axis
Chiou et al. The RING finger E3 ligase RNF25 protects DNA replication forks independently of its canonical roles in ubiquitin signaling
Wang et al. Inhibition of atypical protein kinase Cι induces apoptosis through autophagic degradation of β‐catenin in esophageal cancer cells
US20250127777A1 (en) Dual inhibition of mdm2 and eif2-alpha induces cell death in multiple cancer cell types

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application